tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Melligen Cell Line'

Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment with License for Insulin-Producing Cells

Written by Ι Stock Market Media Group Staff — October 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology.  It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.

Now, almost ...

Read More →
0

Nuvilex Contracts with University of Veterinary Medicine in Vienna to Conduct Preclinical Studies to Develop Diabetes Treatment

SILVER SPRING, MD, October 20, 2014 – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the University to perform “in vitro” and animal studies that use the Cell-in-a-Box® cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has ...

Read More →
0

Nuvilex Secures Worldwide License for Insulin-Producing Cells for Use in Developing Diabetes Treatment

SILVER SPRING, Md., Oct. 16, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants Nuvilex the worldwide rights to use human insulin-producing cells, termed “Melligen” cells, developed by Prof. Ann Simpson and her colleagues at UTS for the development of a treatment for insulin-dependent (Type 1 or ...

Read More →
0
ContactUs.com